The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...
Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback